HEPACAM and myeloid sarcoma: As previously reported (7), anti-EBNA1 antibodies were also associated with MS, particularly anti-EBNA1393–412 (OR: 2.92, 95% CI: 2.17 to 3.94, adjusted P < 1 × 10−14), which includes the known sequence homology to both GlialCAM (18) and CRYAB.